HILO WAVE: two molecular weights in one syringe, and what the licence actually says

Hyaluronic acid behaves differently depending on the size of the molecule. Large chains bind a lot of water and persist longer in tissue, but they do not spread far from where they were placed. Small chains spread readily and are broken down faster. Combining the two is an attempt to have both properties at once, and the manufacturer calls the combination DHC (Dual Hyaluronic Acid Compound).

One thing should be stated plainly. “Mixing them keeps only the advantages of each” is a design intention, not a result measured in patients. It is true that a different molecular weight distribution moves differently in tissue. Whether that difference translates into something a patient notices is not a question we found answered by any study in people.

The concentration deserves its own paragraph. 24mg per cc is higher than what is usually injected as a hydration treatment and sits closer to filler territory. So a meaningful part of what changes immediately after treatment is the volume the gel itself occupies, not hydration alone. That is not a criticism; it is the character of the product, and it is worth knowing before you start rather than after.

The licensed purpose in Korea reads: “injection of cross-linked hyaluronic acid subcutaneously for the temporary improvement of facial wrinkles in adults by physical replacement.” Two words in that sentence matter — physical replacement and temporary.

The product material, meanwhile, uses words like biostimulator, collagen and elastin stimulation, regeneration and remodelling. Those are the manufacturer’s description, not the wording of the licence.

This distinction is not pedantry. It is a question about what to expect. A product that fills physically goes away as it is broken down, and the face returns to where it started. A product that makes the skin build collagen leaves something behind after the material itself is gone. Those are different outcomes on different schedules. On the evidence published so far, the first is clear and the second is still preclinical.

There is one study in an international journal (Roh et al., International Journal of Molecular Sciences 2026;27(7):3038). It is preclinical: DHC was applied in a bleomycin-induced dermal fibrosis model in mice and in UVB-irradiated human skin ex vivo. It reported reduced dermal thickness, reduced collagen deposition and reduced skin hardness, lower α-SMA with higher MMP1, fewer macrophage markers and inflammatory cytokines, and restored antioxidant enzyme activity.

One point should not be missed. The aim of that study was to treat fibrosis — that is, to reduce collagen that has accumulated excessively — and collagen deposition duly went down. That is the opposite direction from “builds collagen” in the aesthetic sense. If you see this paper cited as evidence of collagen stimulation, this is the thing to hold in mind. Promising preclinical signals are real, but they do not tell you how much a wrinkle on a face will change.

• We did not find a clinical trial in living patients. Nothing tells us how much wrinkles improve, how long that lasts, or how often adverse events occur with a denominator attached.
• We found no study comparing it head to head with another booster or filler. There is no basis yet for saying one is better than another.
• We found no independent verification of the manufacturer’s claims that fewer injection points are needed, that it leaves no visible bleb marks, or that it hurts less.
• We could not confirm the Korean device licence number from public sources. It is printed on the box, and you are welcome to check it with us before treatment.
• We could not confirm from public sources whether lidocaine is included.

Because it is hyaluronic acid, hyaluronidase dissolves it. Among the products grouped together as boosters, only the hyaluronic acid ones have this property. The collagen-stimulating products — GOURI, Juvelook, Sculptra — have no known way to be reversed, and neither does CaHA.

This is a genuinely useful safety margin. Two caveats belong with it. First, being reversible is not permission to put in more. Second, hyaluronidase does not pick out only the product that was injected — some of your own hyaluronic acid in that area is broken down with it. Reversal is a contingency, not part of the plan.

Sorted by what they actually do, the boosters we keep fall into three groups: those that make the skin build (GOURI, Juvelook, Sculptra, Radiesse, DCLASSY), those that replace a material the skin has lost (Re2O, CellREDM), and one that improves the regenerative environment (Rejuran). The hyaluronic acid products are none of these — they place the water-binding material itself.

Against BYRYZN, which is in the same class, there are two differences: HILO WAVE carries two molecular weights rather than one, and it is more concentrated. BYRYZN contains lidocaine, while for HILO WAVE we could not confirm that from public sources. But there is no basis for saying either is better, because no study has compared them.

• Skin quality and hydration are the goal, and you would like to see a change relatively early
• It is your first booster and you are more comfortable starting with something that can be undone if it goes wrong
• You want the neck or the backs of the hands looked at alongside the face

• Sagging is the main complaint. Material placed into skin does not raise what has descended
• Placed too superficially under thin skin such as the lower eyelid, it can show through as a bluish tint (the Tyndall effect) or sit as a visible bump. The more concentrated the product, the more the depth of placement decides the result
• You want a change that remains after the material is gone. A collagen-stimulating class is the right direction for that
• Previous adverse reaction to a hyaluronic acid product, active infection or inflammation at the site, pregnancy or breastfeeding

The consultation first separates what is actually short — hydration, collagen, or volume. Products diverge at that fork. Topical anaesthetic is applied, then the product is placed into the dermis in divided deposits, with depth and quantity adjusted to the area and the goal.

The manufacturer’s stated interval is every three months. We prefer not to fix a course in advance: do one, see how the skin responds, then decide. The thinner the human evidence for a product, the more sense that approach makes.

The early change is made by the volume and the water the gel brings with it. So it often looks best immediately afterwards and settles slightly over the following days as swelling resolves. It matters not to read that stage as the result disappearing.

After that it returns gradually towards baseline as the material breaks down. We cannot promise a duration in months — no published study has measured duration in patients. The rate depends on the area, the amount and individual metabolism.

Needle marks and bruising may last a few days, and swelling usually settles within days. For one week, avoid alcohol, saunas, strenuous exercise and strong sun.

Contact us rather than waiting if any of the following happens — one spot that is visibly lumpy, a bluish tint showing through, pain that keeps increasing, or skin that turns pale and mottled. The last of those is a vascular sign and time matters.

Miso Clinic uses genuine HILO WAVE only. If you would like to confirm it, say so before the treatment. We will show you the box and label, and you can have it opened in front of you. The box carries the lot number, the expiry date and the device licence number. Watching it opened at the time is more reliable than any certificate.

Using a genuine product is a record of what was used, not a guarantee of the result. That applies to this product as much as any other.

This reference was written and reviewed by Dr. Lee Chi-Hak, director of Miso Clinic in Daegu, South Korea. The clinic keeps collagen and skin boosters across the ingredient classes available in Korea — liquid PCL (GOURI), PN (Rejuran), hADM (Re2O, CellREDM), CaHA (Radiesse, DCLASSY), cross-linked HA (BYRYZN, HILO WAVE), PDLLA (Juvelook) and PLLA (Sculptra) — along with three lifting devices, and selects between them according to which kind of ageing the face is actually showing. The clinic’s stated approach is restraint: results that are not obviously treatments, and the judgement to do less where less is right.

• Product statement (presentation, active ingredient, licensed purpose, distributor) — as published on the manufacturer’s site hilowave.co.kr, checked September 2026
• Roh H, Nguyen NH, Jung J, et al. Therapeutic Anti-Fibrotic Effects of a Dual Hyaluronic Acid Hybrid Complex in Bleomycin-Induced Dermal Fibrosis and UVB-Irradiated Human Skin. Int J Mol Sci. 2026;27(7):3038. doi:10.3390/ijms27073038 (via PubMed)
• Korean distribution agreement reported May 2025 — exclusive distribution by Neopharm

This page is general medical information, not a diagnosis or a recommendation for any individual. Results vary, and what is actually done is decided in consultation.